Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

Zachary A. Cooper, Vikram R. Juneja, Peter T. Sage, Dennie T. Frederick, Adriano Piris, Devarati Mitra, Jennifer A. Lo, F. Stephen Hodi, Gordon J. Freeman, Marcus W. Bosenberg, Martin McMahon, Keith T. Flaherty, David E. Fisher, Arlene H. Sharpe and Jennifer A. Wargo
Zachary A. Cooper
Departments of 1Surgical Oncology and
2Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vikram R. Juneja
3Harvard-MIT Division of Health Sciences and Technology, Cambridge;
4Department of Microbiology and Immunobiology;
5Harvard Medical School; Divisions of
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter T. Sage
4Department of Microbiology and Immunobiology;
5Harvard Medical School; Divisions of
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennie T. Frederick
6Medical Oncology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adriano Piris
5Harvard Medical School; Divisions of
7Dermatopathology, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devarati Mitra
5Harvard Medical School; Divisions of
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer A. Lo
5Harvard Medical School; Divisions of
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Stephen Hodi
5Harvard Medical School; Divisions of
9Department of Medical Oncology, Dana-Farber Cancer Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon J. Freeman
5Harvard Medical School; Divisions of
9Department of Medical Oncology, Dana-Farber Cancer Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus W. Bosenberg
11Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin McMahon
12Helen Diller Family Comprehensive Cancer Center; and
13Department of Cell and Molecular Pharmacology, University of California San Francisco, San Francisco, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith T. Flaherty
5Harvard Medical School; Divisions of
6Medical Oncology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Fisher
5Harvard Medical School; Divisions of
8Dermatology, Massachusetts General Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arlene H. Sharpe
4Department of Microbiology and Immunobiology;
5Harvard Medical School; Divisions of
10Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer A. Wargo
Departments of 1Surgical Oncology and
2Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jwargo@mdanderson.org
DOI: 10.1158/2326-6066.CIR-13-0215 Published July 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: April 2014 to January 2021

AbstractFull-text HTMLPDF
Total806964344779

Cited By

Article Information

Volume 2, Issue 7, pp. 643-654

DOI 
https://doi.org/10.1158/2326-6066.CIR-13-0215
PubMed 
24903021

Published By 
American Association for Cancer Research
Print ISSN 
2326-6066
Online ISSN 
2326-6074
History 
  • Received December 4, 2013
  • Revision received April 4, 2014
  • Accepted April 21, 2014
  • Published first April 29, 2014.

Article Versions

  • Previous version (April 29, 2014 - 06:35).
  • Previous version (June 5, 2014 - 06:59).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2014 American Association for Cancer Research.

Author Information

  1. Zachary A. Cooper1,2,
  2. Vikram R. Juneja3,4,5,
  3. Peter T. Sage4,5,
  4. Dennie T. Frederick6,
  5. Adriano Piris5,7,
  6. Devarati Mitra5,
  7. Jennifer A. Lo5,
  8. F. Stephen Hodi5,9,
  9. Gordon J. Freeman5,9,
  10. Marcus W. Bosenberg11,
  11. Martin McMahon12,13,
  12. Keith T. Flaherty5,6,
  13. David E. Fisher5,8,
  14. Arlene H. Sharpe4,5,10, and
  15. Jennifer A. Wargo1,2,*
  1. Authors' Affiliations: Departments of 1Surgical Oncology and
  2. 2Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas;
  3. 3Harvard-MIT Division of Health Sciences and Technology, Cambridge;
  4. 4Department of Microbiology and Immunobiology;
  5. 5Harvard Medical School; Divisions of
  6. 6Medical Oncology,
  7. 7Dermatopathology, and
  8. 8Dermatology, Massachusetts General Hospital;
  9. 9Department of Medical Oncology, Dana-Farber Cancer Institute;
  10. 10Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts;
  11. 11Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut;
  12. 12Helen Diller Family Comprehensive Cancer Center; and
  13. 13Department of Cell and Molecular Pharmacology, University of California San Francisco, San Francisco, California
  1. ↵*Corresponding Author:
    Jennifer A. Wargo, University of Texas MD Anderson Cancer Center, Surgical Oncology, 1515 Holcombe Boulevard SCT17.6010, Houston, TX 77030. Phone: 713-745-1553; Fax: 713-745-2436; E-mail: jwargo{at}mdanderson.org
  1. Z.A. Cooper, V.R. Juneja, P.T. Sage, A.H. Sharpe, and J.A. Wargo contributed equally to this work.

View Full Text
PreviousNext
Back to top
Cancer Immunology Research: 2 (7)
July 2014
Volume 2, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Zachary A. Cooper, Vikram R. Juneja, Peter T. Sage, Dennie T. Frederick, Adriano Piris, Devarati Mitra, Jennifer A. Lo, F. Stephen Hodi, Gordon J. Freeman, Marcus W. Bosenberg, Martin McMahon, Keith T. Flaherty, David E. Fisher, Arlene H. Sharpe and Jennifer A. Wargo
Cancer Immunol Res July 1 2014 (2) (7) 643-654; DOI: 10.1158/2326-6066.CIR-13-0215

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Zachary A. Cooper, Vikram R. Juneja, Peter T. Sage, Dennie T. Frederick, Adriano Piris, Devarati Mitra, Jennifer A. Lo, F. Stephen Hodi, Gordon J. Freeman, Marcus W. Bosenberg, Martin McMahon, Keith T. Flaherty, David E. Fisher, Arlene H. Sharpe and Jennifer A. Wargo
Cancer Immunol Res July 1 2014 (2) (7) 643-654; DOI: 10.1158/2326-6066.CIR-13-0215
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • CD28 Mutation Enhances CAR T-cell Function
  • ICV-Delivered CD19-CAR T Cells for CNS and Systemic Lymphoma
  • Activin A Mediates Radiation-Induced Antitumor Immunity
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement